ScoreCarder and ohm, I appreciate the pushback, healthy skepticism is the fuel of due diligence. However, you both are looking at the Regulatory and Biological Physics of 2021, while the world has fundamentally shifted into the Makary-Prasad Paradigm of 2026.
Let’s dismantle the Rare Disease Only and PD-L1 is Negative myths with the actual unsealed documents and transcripts from the last two weeks.
1. The Trojan Horse of the 2/23 Guidance
ScoreCarder, you’re right about the title of the February 23, 2026 FDA Guidance . But as noted by top regulatory law firms, the title is the wrapper, while the policy inside is the gift.
According to the Arnold & Porter Advisory (Feb 25, 2026) , this guidance explicitly:
In a pivotal interview on CNBC’s Squawk Box and a corresponding press release, Commissioner Makary explicitly linked the "Plausible Mechanism" logic to the FDA’s new One-Trial Default Policy.
This is the Regulatory Pivot. The FDA is using the "Ultra-Rare" guidance as the legal sandbox to codify Mechanistic Evidence as a replacement for raw patient volume.
Furthermore, in his [url=https://www.cnbc.com/video/2026/02/26/fda-commissioner-dr-makary-on-rare-disease-therapy-approvals-internal-politics-at-the-agency.html[/url], Commissioner Marty Makary stated:
The FDA is using "Ultra-Rare" as the legal sandbox to codify Mechanistic Evidence (like Leronlimab's CCR5 blockade) as a replacement for massive Phase 3 volume.
The "Bridge to Oncology" (Project Pragmatica)
Nothing to do with CytoDyn's indications? On February 26th, Makary specifically addressed how this framework interacts with the Oncology Center of Excellence:
2. Addressing ohm's argument, your point about PD-L1 being "protective" is a half-truth that misses the Combination Strategy.
In a "Cold Tumor" (like most MSS-CRC), there is zero PD-L1 expression. This means the tumor is invisible to the Immune System and unresponsive to blockbuster drugs like Keytruda. Keytruda needs PD-L1 to work; it is the "anchor" for the drug.
As documented in the CytoDyn December 8, 2025 Press Release and the AACR February 2026 Abstract (PS5-02-30) :
Leronlimab upregulates PD-L1 in 88% of patients.
This is called "Unmasking" or "Priming."
By inducing PD-L1, Leronlimab turns a "Cold" (invisible) Tumor into a "Hot" (actionable) Tumor that an Immune Checkpoint Inhibitor (ICI) can finally attack.
The results? 100% survival (n=5/5) in the mTNBC cohort that showed this upregulation and then received an ICI. If CytoDyn told the FDA they increased PD-L1, the FDA wouldn't think they were "crazy", they would see Leronlimab rescuing the $30B PD-1/PD-L1 market.
3. The "Cure Coefficient" Calculation
The FDA’s new flexibility relies on the Cure Coefficient (C_c), which compares trial results to well-characterized natural histories (a key feature of the 2/23 guidance).
C_c = Overall Survival (Leronlimab + Combo) / Overall Survival (Historical Baseline (Standard of Care))
If the MSS-CRC data unmasked between March 17 and April 17 shows a C_c > 1.5, the "Plausible Mechanism" of PD-L1 induction becomes the Pivotal Registration Data.
The Bottom Line:
The Body Count vs. The Bread Crumbs
Bread crumbs? In reality, this is the Audit Trail of a Buyout.
Big Pharma doesn't buy drugs; they buy Regulatory Certainty.
Old World: Big Pharma waits 5 years for a Phase 3.
Makary World: Big Pharma sees the Feb 20th Mechanistic Data, sees the Feb 26th Policy Shift, and moves in now because the 12-week ctDNA clearance (The Body Count) is legally sufficient for approval under the PMF.
The Rare Disease label is the wrapping paper; the Mechanistic Data is the gift. CytoDyn is sitting on a Pan-Tumor Key which fits the exact lock the FDA just finished installing on February 26th.
The data soon drops, and when it hits a Mechanistic-First FDA, the share price re-set won't be a crawl, it gaps-up.
CytoDyn is currently flying the Plane directly onto the Landing Strip the FDA finished paving on February 23rd.
Let the tape play out.
Let’s dismantle the Rare Disease Only and PD-L1 is Negative myths with the actual unsealed documents and transcripts from the last two weeks.
1. The Trojan Horse of the 2/23 Guidance
ScoreCarder, you’re right about the title of the February 23, 2026 FDA Guidance . But as noted by top regulatory law firms, the title is the wrapper, while the policy inside is the gift.
According to the Arnold & Porter Advisory (Feb 25, 2026) , this guidance explicitly:
Quote:"...signals a shift to a single trial with confirmatory evidence default for ALL drugs and biologics."
In a pivotal interview on CNBC’s Squawk Box and a corresponding press release, Commissioner Makary explicitly linked the "Plausible Mechanism" logic to the FDA’s new One-Trial Default Policy.
Quote:The Quote (Makary, Feb 26, 2026):
"The Plausible Mechanism Framework isn't just a niche pathway for the few; it is a signal to the entire industry that the 'Two-Trial Dogma' is over for any therapy with a known biological cause. If you can show us the 'Why' (Mechanistic Data) and the 'How' (Target Engagement), we are moving to a single-trial requirement as the default for all unmet needs, including oncology."
This is the Regulatory Pivot. The FDA is using the "Ultra-Rare" guidance as the legal sandbox to codify Mechanistic Evidence as a replacement for raw patient volume.
Furthermore, in his [url=https://www.cnbc.com/video/2026/02/26/fda-commissioner-dr-makary-on-rare-disease-therapy-approvals-internal-politics-at-the-agency.html[/url], Commissioner Marty Makary stated:
Quote:"The Plausible Mechanism Framework isn't just a niche pathway... it is a signal to the entire industry that the 'Two-Trial Dogma' is over for any therapy with a known biological cause... including oncology."
The FDA is using "Ultra-Rare" as the legal sandbox to codify Mechanistic Evidence (like Leronlimab's CCR5 blockade) as a replacement for massive Phase 3 volume.
The "Bridge to Oncology" (Project Pragmatica)
Nothing to do with CytoDyn's indications? On February 26th, Makary specifically addressed how this framework interacts with the Oncology Center of Excellence:
Quote:The Quote (Makary, Feb 26, 2026):
"In oncology, we’ve spent decades chasing p-values in massive trials that often ignore the underlying biology. By aligning our Plausible Mechanism logic with Project Pragmatica, we are allowing sponsors to use surrogate markers—like ctDNA clearance and biomarker upregulation—to secure earlier approval. We want the science of the mechanism to lead the way."
2. Addressing ohm's argument, your point about PD-L1 being "protective" is a half-truth that misses the Combination Strategy.
In a "Cold Tumor" (like most MSS-CRC), there is zero PD-L1 expression. This means the tumor is invisible to the Immune System and unresponsive to blockbuster drugs like Keytruda. Keytruda needs PD-L1 to work; it is the "anchor" for the drug.
As documented in the CytoDyn December 8, 2025 Press Release and the AACR February 2026 Abstract (PS5-02-30) :
Leronlimab upregulates PD-L1 in 88% of patients.
This is called "Unmasking" or "Priming."
By inducing PD-L1, Leronlimab turns a "Cold" (invisible) Tumor into a "Hot" (actionable) Tumor that an Immune Checkpoint Inhibitor (ICI) can finally attack.
The results? 100% survival (n=5/5) in the mTNBC cohort that showed this upregulation and then received an ICI. If CytoDyn told the FDA they increased PD-L1, the FDA wouldn't think they were "crazy", they would see Leronlimab rescuing the $30B PD-1/PD-L1 market.
3. The "Cure Coefficient" Calculation
The FDA’s new flexibility relies on the Cure Coefficient (C_c), which compares trial results to well-characterized natural histories (a key feature of the 2/23 guidance).
C_c = Overall Survival (Leronlimab + Combo) / Overall Survival (Historical Baseline (Standard of Care))
If the MSS-CRC data unmasked between March 17 and April 17 shows a C_c > 1.5, the "Plausible Mechanism" of PD-L1 induction becomes the Pivotal Registration Data.
The Bottom Line:
The Body Count vs. The Bread Crumbs
Bread crumbs? In reality, this is the Audit Trail of a Buyout.
Big Pharma doesn't buy drugs; they buy Regulatory Certainty.
Old World: Big Pharma waits 5 years for a Phase 3.
Makary World: Big Pharma sees the Feb 20th Mechanistic Data, sees the Feb 26th Policy Shift, and moves in now because the 12-week ctDNA clearance (The Body Count) is legally sufficient for approval under the PMF.
The Rare Disease label is the wrapping paper; the Mechanistic Data is the gift. CytoDyn is sitting on a Pan-Tumor Key which fits the exact lock the FDA just finished installing on February 26th.
The data soon drops, and when it hits a Mechanistic-First FDA, the share price re-set won't be a crawl, it gaps-up.
CytoDyn is currently flying the Plane directly onto the Landing Strip the FDA finished paving on February 23rd.
Let the tape play out.
9
